SGS Expands Cutting-Edge Spray Drug Delivery Testing Capabilities in Belgium Health Science Laboratory

November 06, 2024 08:10 PM AEDT | By EIN Presswire
 SGS Expands Cutting-Edge Spray Drug Delivery Testing Capabilities in Belgium Health Science Laboratory
Image source: EIN Presswire
GENEVA, BELGIUM, November 6, 2024 /EINPresswire.com/ -- SGS, the world’s leading testing, inspection and certification company, has announced an expansion in its spray drug delivery testing capabilities at their laboratory in Wavre, Belgium.

Utilizing the latest Malvern Spraytec system, SGS can now accurately measure droplet size in real-time during the spraying event, typically occurring within a fraction of a second. In line with US Food and Drug Administration (FDA) regulations, sprays are classified as combination products, meaning the formulation and delivery system must be tested together. As a result, SGS technicians at the Wavre laboratory have paired the Malvern Spraytec system with the Mighty Runt actuator to precisely assess how factors like device actuation – including pump velocity and force – and droplet size impact drug delivery.

From sinus congestion treatments to vaccines, sprays are now a popular method for delivering medication due to their non-invasive nature and rapid absorption. Since droplet size is a key factor in spray efficacy, it is crucial to assess the drug product in real-world conditions, including storage and patient usage habits. Understanding droplet size is essential for developing drug products that deliver optimal patient outcomes.

The Malvern Spraytec system employs advanced laser technology to measure the diffraction patterns created as light scatters off droplets in the spray plume. With a data acquisition rate of up to 10 kilohertz, it captures detailed profiles of droplets of between 20 and 120 microns. This high-resolution data enables SGS experts to provide in-depth insights into spray formulations and delivery devices, thereby supporting optimized drug efficiency.

SGS’s state-of-the-art laboratory in Wavre, Belgium, is part of a global network extending across America, Europe and Asia-Pacific. Established in 1971 and based in Wavre, Brussels, the facility is GMP- and FDA-certified and has over 50 years of experience as a contract service organization, providing integrated solutions from preclinical activities to phase I-IV trails for research, development and quality control testing.

SGS is committed to delivering high-level insights that fuel technological advances in the pharmaceutical industry.

With expertise in analytical testing, formulation development, clinical research and clinical manufacturing, SGS is well-positioned to support the pharmaceutical industry across the full drug development and commercialization cycle, ensuring the delivery of safe, effective and compliant medicines to international markets.

About SGS
We are SGS – the world’s leading testing, inspection and certification company. We are recognized as the global benchmark for sustainability, quality and integrity. Our 99,600 employees operate a network of 2,600 offices and laboratories around the world.​​​​​​​

For further information, please contact:

Jackie Brown
Sugarloaf Marketing Ltd.
+44 7792970919
[email protected]

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.
This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.


AU_advertise

Advertise your brand on Kalkine Media

Sponsored Articles


Investing Ideas

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.